1Thomson BN, Ban ring SW, Gibbs P, et al. Pancreatic cancer-current management[ J]. Aust Fam Physician,2006,35 (4) :212. 被引量：1
2Sultana A, Smith C, Cunningham D, et al. Metaanalyses of chemo ther- apy for locally advanced andmetastatic pancreatic cancer [ J ]. J Clin Oncol,2007,25 ( 18 ) :2607. 被引量：1
3Coluci G,Labianca R,Di Costanzo F,et al. Randomized phase Ⅲ tnal of gemcitabine plus cisplatin compared withsingle-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study[ J]. J Clin Onco1,2010,28 ( 10 ) : 1645. 被引量：1
4Cunningham D, Chau I, Stocken DD, et al. Phase Ⅲ randomized com- parison of gemcitabineversus gemcitabine plus capecitabine in patients- with advanced pancreatic cancer [ J ]. J Clin Oncol, 2009,27 ( 33 ) : 5513. 被引量：1
1[1]Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002.Cancer J Clin, 2002, 52( 1 ): 23. 被引量：1
2[5]Robert N, Leyland-Jones B, Asmar L, et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advance breast cancer. Breast Cancer Res Treat, 2002, 76(Supple): 37. 被引量：1
3[6]Henderson C, Berry DA, Denetri GD, et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003, 21 (6):976. 被引量：1
4[8]Talbot DC, Moiseyenko V, van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002, 86(9): 1367. 被引量：1
5[9]O′ Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthra cycline-pretreated patients with advanced breast cancer: phase Ⅲ trial results. J Clin Oncol, 2002, 20(12): 2812. 被引量：1
6[10]Venturini M, Durando A, Garrone O, et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer, 2003, 97(5):1174. 被引量：1
7[11]Biganzoil L, Martin M, Twelves C. Moving forward with capecitabine: a glimpse of the future. Oncologist, 2002, 7 (Suppl 6):29. 被引量：1
8[14]The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal womem with early breast cancer: first results of the ATAC randomized trial. Lancet, 2002, 359: 2131. 被引量：1
9[15]Nahboltz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen, a first line therapy for advanced breast cancer in postmenopausal women: results of a north American multicenter randomized trial. J Clin Oncol, 2000, 18(22): 3758. 被引量：1
10[16]Buzdar AU. New generation aromatase inhibitors from the advance to the adjuvant setting. Breast Cancer Res Treat, 2002, 75(Suppl 1): 13. 被引量：1
